sedation in the intensive care unit with remifentanilpropofol versus midazolamfentanyl a randomised, open-label, pharmacoeconomic trial镇静在重症监护室remifentanilpropofol与midazolamfentanyl随机、非盲、pharmacoeconomic审判.pdfVIP

下载本文档

1
0
约6.3万字
约 9页
2017-09-11 发布于上海
举报
版权申诉

sedation in the intensive care unit with remifentanilpropofol versus midazolamfentanyl a randomised, open-label, pharmacoeconomic trial镇静在重症监护室remifentanilpropofol与midazolamfentanyl随机、非盲、pharmacoeconomic审判.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

sedation in the intensive care unit with remifentanilpropofol versus midazolamfentanyl a randomised, open-label, pharmacoeconomic trial镇静在重症监护室remifentanilpropofol与midazolamfentanyl随机、非盲、pharmacoeconomic审判

Available online /content/10/3/R91 Vol 10 No 3 Open Access Research Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial 1 1 2 2 Bernd Muellejans , Thomas Matthey , Joachim Scholpp and Markus Schill 1Department of Anaesthesiology and Intensive Care Medicine, Heart Centre Mecklenburg-Vorpommern, Germany 2Medical Department, GlaxoSmithKline, Munich, Germany Corresponding author: Bernd Muellejans, dr.muellejans@drguth.de Received: 26 Jan 2006 Revisions requested: 14 Feb 2006 Revisions received: 8 Mar 2006 Accepted: 8 May 2006 Published: 15 Jun 2006 Critical Care 2006, 10:R91 (doi:10.1186/cc4939) This article is online at: /content/10/3/R91 © 2006 Muellejans et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Introduction Remifentanil is an opioid with a unique supplemented only in the case of insufficient sedation at pharmacokinetic profile. Its organ-independent elimination and maximal remifentanil dose. Patients in the midazolam/fentanyl short context-sensitive half time of 3 to 4 minutes lead to a highly group received midazolam (0.02 to 0.2 mg kg-1 h-1) and fentanyl predictable offset of action. We tested the hypothesis that with (1.0 to 7.0 µg kg-1 h-1). For treatment of pain